Angiodynamics Inc: Form 10-Q for the period ended Aug 31, 2023
Filed with the SEC on Oct 5, 2023 and accepted by EDGAR at Oct 5, 2023, 17:15 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-08-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-06-01 to 2023-08-31 | $78.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-06-01 to 2023-08-31 | $38.6m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-06-01 to 2023-08-31 | $40.1m | us-gaap:GrossProfit |
| Research and development | 3 months2023-06-01 to 2023-08-31 | $7.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-06-01 to 2023-08-31 | $35.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-06-01 to 2023-08-31 | −$119.0k | us-gaap:InterestExpense |
| Income tax | 3 months2023-06-01 to 2023-08-31 | −$11.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-06-01 to 2023-08-31 | $45.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-06-01 to 2023-08-31 | $1.15 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-06-01 to 2023-08-31 | $1.15 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-06-01 to 2023-08-31 | 39,968,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-06-01 to 2023-08-31 | −$25.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-06-01 to 2023-08-31 | $791.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-08-31 | $57.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-08-31 | $175.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-08-31 | $493.9m | us-gaap:Assets |
| Current liabilities | At period end2023-08-31 | $57.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-08-31 | $66.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-08-31 | $427.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-23-033979. Last ingested by Listed: Oct 30, 2026, 16:23 ET. Listed shows no prices and gives no investment advice.